半乳糖凝集素3(GAL3)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Galectin 3 (GAL3) ,etc. by FLIA (Flow Luminescence Immunoassay)
LGALS3; CBP35; GALBP; GALIG; MAC2; 35 kDa lectin; Carbohydrate-binding protein 35; Galactose-specific lectin 3; Galactoside-binding protein; Laminin-binding protein; Lectin L-29
(注:單次混測多因子不超過8個指標(biāo) )
- 編號LMA303Hu
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時長3.5h
- 檢測范圍0.01-10ng/mL
- 靈敏度最小可檢測劑量小于等于0.003 ng/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價格 ¥ 2359 ¥ 2449 ¥ 2586 ¥ 2767 ¥ 2948 ¥ 3221 ¥ 3629 計算器 ¥ 4536 添加到價格計算器
- 欲了解實(shí)際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測半乳糖凝集素3(GAL3)等多因子檢測試劑盒(流式熒光發(fā)光法),經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測,因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的半乳糖凝集素3(GAL3)等多因子檢測試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測定并計算其均值,回收率為測定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 98-105 | 102 |
EDTA plasma(n=5) | 84-103 | 94 |
heparin plasma(n=5) | 85-104 | 91 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次,分別計算不同濃度樣本的平均值及SD值。
批間差:選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定,每個樣本使用同一試劑盒重復(fù)測定8次,分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的半乳糖凝集素3(GAL3)等多因子檢測試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測樣本,線性范圍即為稀釋后樣本中半乳糖凝集素3(GAL3)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 78-91% | 82-101% | 81-97% | 96-104% |
EDTA plasma(n=5) | 82-104% | 79-102% | 95-102% | 91-99% |
heparin plasma(n=5) | 98-105% | 78-90% | 98-105% | 96-104% |
穩(wěn)定性
經(jīng)測定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠)標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL,
37°C酶標(biāo)板振蕩器孵育90分鐘;
3. 磁吸甩干,加檢測溶液A100μL,37°C酶標(biāo)板振蕩器孵育60分鐘;
4. 磁吸洗板3次;
5. 加檢測溶液B100μL,37°C振動孵育30分鐘;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將半乳糖凝集素3(GAL3)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠,其中的半乳糖凝集素3(GAL3)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的半乳糖凝集素3(GAL3)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的半乳糖凝集素3(GAL3)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA303Hu01 | 半乳糖凝集素3(GAL3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
EPA303Hu61 | 半乳糖凝集素3(GAL3)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA303Hu01 | 半乳糖凝集素3(GAL3)活性蛋白 | Cell?culture;?Activity?Assays. |
PAA303Hu01 | 半乳糖凝集素3(GAL3)多克隆抗體 | WB; IHC; IF |
FAA303Hu01 | 抗半乳糖凝集素3(GAL3)多克隆抗體 | Flow cytometry. |
LAA303Hu71 | 半乳糖凝集素3(GAL3)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
LAA303Hu81 | 半乳糖凝集素3(GAL3)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
MAA303Hu24 | 半乳糖凝集素3(GAL3)單克隆抗體 | WB; IHC; ICC; IP. |
MAA303Hu23 | 半乳糖凝集素3(GAL3)單克隆抗體 | WB; IHC; ICC; IP. |
MAA303Hu22 | 半乳糖凝集素3(GAL3)單克隆抗體 | WB; IHC |
MAA303Hu21 | 半乳糖凝集素3(GAL3)單克隆抗體 | WB; IHC; ICC; IP. |
FAA303Hu02 | 抗半乳糖凝集素3(GAL3)單克隆抗體 | Flow cytometry. |
SEA303Hu | 半乳糖凝集素3(GAL3)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
MEA303Hu | 半乳糖凝集素3(GAL3)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA303Hu | 半乳糖凝集素3(GAL3)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
KSA303Hu01 | 半乳糖凝集素3(GAL3)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | 自己動手制作ELISA試劑盒的主要材料 |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Clinica Chimica Acta | Galectin-1 and galectin-3: plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population [Pubmed:25578395] |
Scientific Reports | Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with Hypertension [PubMed: 25747153] |
Int J Mol Sci | The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension [PubMed: 25984599] |
Scientifi Reportcs | Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices [PubMed: 26582585] |
Clin Chim Acta | Galectin-1 and galectin-4: Plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population [PubMed: 25578396] |
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION | Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4. [pubmed:28431936] |
昆明醫(yī)科大學(xué)學(xué)報 | 半乳糖凝集素3 在COPD 和肺癌中的表達(dá)及其意義. [2095610X] |
Archives of Medical Science | Can we define migraine patients with blood high-sensitivity C-reactive protein and galectin-3 levels in the emergency department? [publication:305625095] |
Biosensors & Bioelectronics | A sensitive sandwich-type immunosensor for the detection of galectin-3 based on N-GNRs-Fe-MOFs@AuNPs nanocomposites and a novel AuPt-methylene blue nanorod. [pubmed:29096363] |
Scientific Reports | The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction. [pubmed:28827564] |
Clinica Chimica Acta | Galectin-3 in patients with coronary heart disease and atrial fibrillation [Pubmed:29287900] |
Advances in Experimental?Medicine?and?Biology | Molecules of Damage-Associated Patterns in Bronchoalveolar Lavage Fluid and Serum in Chronic Obstructive Pulmonary Disease [Pubmed:29429028] |
FASEB?Journal | Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure [Pubmed: 30230922] |
american journal of physiology-heart and circulatory physiology | Macrophage galectin-3 enhances intimal translocation of vascular calcification in diabetes mellitus [Pubmed: 32216615] |
Cardiology | Galectin-3 Induces Atrial Fibrosis by Activating the TGF-β1/Smad Pathway in Patients with Atrial Fibrillation [Pubmed: 32516780] |
AUSTRALIAN DENTAL JOURNAL | The effect of initial periodontal treatment on gingival crevicular fluid galectin?\3 levels in participants with periodontal disease [33378559] |
Cell Death & Disease | Trajectory modeling of endothelial-to-mesenchymal transition reveals galectin-3 as a mediator in pulmonary fibrosis [33771973] |
Int J Clin Pract | Serum Galectin?\3 Levels in Patients with Psoriasis [34137138] |
Phytomedicine | Zerumbone, a humulane sesquiterpene from Syringa pinnatifolia, attenuates cardiac fibrosis by inhibiting of the TGF-β1/Smad signaling pathway after myocardial?… [Pubmed:35405613] |
Medicine | Regulatory T cells, damage-associated molecular patterns, and myeloid-derived suppressor cells in bronchoalveolar lavage fluid interlinked with chronic obstructive?… [Pubmed:35687771] |